http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 12 Mar 2026 16:17:56 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/Capricor+Therapeutics+%28CAPR%29+Misses+Q4+EPS+by+11c/26153338.html <p>Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.62), $0.11 worse than the analyst estimate of ($0.51). </p><p>For earnings history and earnings-related data on Capricor Therapeutics (CAPR) <a href="http://www.streetinsider.com/ec_earnings.php?q=CAPR">click here</a>.</p> http://www.streetinsider.com/Earnings/Capricor+Therapeutics+%28CAPR%29+Misses+Q4+EPS+by+11c/26153338.html Thu, 12 Mar 2026 16:17:56 -0400 CAPR http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html <ul type="disc"><li style="text-align:justify;"><em>Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026</em></li><li style="text-align:justify;"><em>Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)</em></li><li style="text-align:justify;"><em>Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits</em></li><li style="text-align:justify;"><em>San Diego GMP manufacturing facility operational to support potential commercial launch</em></li><li style="text-align:justify;"><em>Capricor uplisted to the Nasdaq Global Select Market</em></li><li style="text-align:justify;"><em>Cash balance of approximately $318 million expected to support operations through 2027</em></li><li style="text-align:justify;"><em>Conference call and webcast today at 4:30 p.m. ET</em><br/><br/></li></ul> <p align="justify">SAN DIEGO, March 12, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Capricor+Therapeutics+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results+and+Provides+Corporate+Update/26152759.html Thu, 12 Mar 2026 16:01:00 -0400 A.06822034 A.13662202 A.14229788 A.25015717 A.31066700 CAPR O.00063751 O.02298954 O.03796190 O.09788428 O.20026344 O.22422661